Ads
related to: wet macular degeneration injections available- What Does EYLEA HD Treat?
Learn About The Conditions
Which EYLEA HD Can Help Treat
- EYLEA HD Patient Support
Learn About Financial Support
That May Be Available To You
- EYLEA HD Resource Library
Useful Digital Resources & Tools
To Support Your Treatment Journey
- Appointment Tips
Get Tips And Useful Information
To Talk To A Specialist
- Why EYLEA HD?
Learn More About This Treatment
To See If EYLEA HD Is Right For You
- Sign Up For More Info
Sign Up To Receive More Resources
And Information About EYLEA HD
- What Does EYLEA HD Treat?
wiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Ixoberogene soroparvovec (Ixo-vec, also known as ADVM-022), is a gene therapy developed by Adverum Biotechnologies for wet age-related macular degeneration. It is delivered via the viral vector AAV.7m8. [1] [2]
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
“Despite new treatments entering the wet AMD market, there remains a need for safe and durable treatments that provide sustained treatment while decreasing the patient’s need for frequent injections,” said Ashkan M. Abbey, M.D., a principal investigator in the LUGANO clinical trial and Director of Clinical Research at Texas Retina Associates.
In neovascular age-related macular degeneration (nAMD), key intravitreal agents include Adverum Biotechnologies’ ixoberogene soroparvovec (Ixo-vec) and 4D Molecular Therapeutics’ 4D-150. [4] Both use innovative mechanisms to produce anti-VEGF proteins directly within the eye, significantly reducing the need for frequent anti-VEGF injections.
Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. [1] It is used to treat various eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye such as endophthalmitis. [1]
Ad
related to: wet macular degeneration injections available